Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.
Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF 3rd, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR.
Ceglia I, et al. Among authors: masiello f.
Exp Hematol. 2016 Dec;44(12):1138-1155.e4. doi: 10.1016/j.exphem.2016.08.007. Epub 2016 Aug 31.
Exp Hematol. 2016.
PMID: 27592389
Free PMC article.